Home > Insider Trading > Filing (0001225208-18-015758)

Filing Details

Accession Number:: 0001225208-18-015758
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-11-20 20:25:49
Reporting Period:: 2018-11-19

Accepted Time:: 2018-11-20 20:25:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1099800	Edwards Lifesciences Corp	EW	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	364316614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204551	A Michael Mussallem	One Edwards Way Irvine CA 92614	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-11-19	32,900	$42.73	76,026	No	4	M	Direct
Common Stock	Disposition	2018-11-19	500	$155.06	75,526	No	4	S	Direct
Common Stock	Disposition	2018-11-19	1,100	$153.99	74,426	No	4	S	Direct
Common Stock	Disposition	2018-11-19	4,200	$152.06	70,226	No	4	S	Direct
Common Stock	Disposition	2018-11-19	8,340	$151.19	61,886	No	4	S	Direct
Common Stock	Disposition	2018-11-19	18,760	$150.18	43,126	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Acquire)	Disposition	2018-11-19	32,900	$0.00	32,900	$42.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
122,400	2012-06-09	2019-05-08	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	123,931	Indirect	401(k)
Common Stock	745,400	Indirect	By Living Trust

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.
This transaction was executed in multiple trades at prices ranging from $154.87 to $155.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $153.59 to $154.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $151.70 to $152.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $150.70 to $151.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $149.68 to $150.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.